OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
2023.Dec.29
未分類
Corporate
Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.
2023.Dec.06
未分類
Corporate
OBI Pharma proprietary ADC technology platform “plug and play”
2023.Nov.23
未分類
Corporate
Award & Certification
OBI Achieves ISO/IEC 27001 International Information Security Certification
2023.Nov.01
未分類
Sustainability
OBI VOLUNTEERS ON A MISSION!
2023.Jun.02
Corporate
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. appointed as Chief Executive Officer
2023.Apr.20
Corporate
Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
2023.Apr.10
Corporate
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
2022.Jul.05
Corporate
OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs
2022.Jun.06
Corporate
Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424
